Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Sells 72,236 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK)

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. decreased its holdings in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) by 18.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 313,689 shares of the company's stock after selling 72,236 shares during the period. Scholar Rock makes up approximately 2.0% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s holdings, making the stock its 18th largest position. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned approximately 0.33% of Scholar Rock worth $10,085,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of SRRK. CWM LLC increased its stake in shares of Scholar Rock by 152.8% during the 1st quarter. CWM LLC now owns 996 shares of the company's stock worth $32,000 after purchasing an additional 602 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Scholar Rock in the 4th quarter worth about $85,000. NEOS Investment Management LLC acquired a new stake in shares of Scholar Rock in the fourth quarter worth $209,000. Tema Etfs LLC purchased a new position in Scholar Rock in the fourth quarter valued at about $209,000. Finally, Mackenzie Financial Corp acquired a new position in Scholar Rock during the 4th quarter worth approximately $212,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Akshay Vaishnaw sold 6,750 shares of the firm's stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $29.72, for a total value of $200,610.00. Following the transaction, the insider owned 616,205 shares of the company's stock, valued at approximately $18,313,612.60. This trade represents a 1.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joshua Reed sold 5,400 shares of the business's stock in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $29.72, for a total transaction of $160,488.00. Following the sale, the director directly owned 15,732 shares of the company's stock, valued at approximately $467,555.04. This trade represents a 25.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,654 shares of company stock valued at $3,265,961 over the last three months. Company insiders own 13.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on SRRK shares. Wedbush restated an "outperform" rating and issued a $50.00 price target on shares of Scholar Rock in a research report on Wednesday, June 18th. Lifesci Capital upgraded shares of Scholar Rock to a "strong-buy" rating in a report on Tuesday, June 3rd. Finally, Cantor Fitzgerald assumed coverage on shares of Scholar Rock in a research report on Thursday, July 17th. They set an "overweight" rating for the company. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $42.67.

Scholar Rock Stock Performance

Shares of NASDAQ:SRRK traded down $1.14 during trading on Tuesday, hitting $39.98. 1,615,723 shares of the stock were exchanged, compared to its average volume of 1,325,356. The company's fifty day simple moving average is $34.10 and its 200-day simple moving average is $35.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.25 and a current ratio of 10.25. The company has a market capitalization of $3.80 billion, a price-to-earnings ratio of -15.80 and a beta of 0.33. Scholar Rock Holding Corporation has a 1-year low of $6.76 and a 1-year high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period last year, the company posted ($0.59) earnings per share. Sell-side analysts expect that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.